Moderna
inventory jumped by double digits Tuesday on constructive information about the company’s most cancers vaccine, but Chardan Funds Markets believes the biotech company’s shares will not go substantially bigger.
Moderna
(ticker: MRNA) and
Merck
(MRK) mentioned on Tuesday that using Moderna ‘s experimental cancer vaccine with
Merck
‘s Keytruda in melanoma people diminished the danger of death in a Phase 2 trial. Modern’s stock jumped 20% to near at $197.54.
Moderna
inventory jumped by double digits Tuesday on constructive information about the company’s most cancers vaccine, but Chardan Funds Markets believes the biotech company’s shares will not go substantially bigger.
Moderna
(ticker: MRNA) and
Merck
(MRK) mentioned on Tuesday that using Moderna ‘s experimental cancer vaccine with
Merck
‘s Keytruda in melanoma people diminished the danger of death in a Phase 2 trial. Modern’s stock jumped 20% to near at $197.54.
